Developer docs
API playgroundTry for free, no card

Search company profiles

Orca Bio

Full company profile

uuid00005ky

Namestring
Orca Bio
Legal namestring
Orca Biosystems Inc.
Websiteurl
orcabio.com
Company typeenum
Private
Founded yearint
2016
Descriptiontext

Orca Bio is a late-stage clinical biotechnology company developing high-precision allogeneic T-cell immunotherapies for the treatment of hematologic malignancies, including acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), myelodysplastic syndromes (MDS), and mixed-phenotype acute leukemia (MPAL), with ongoing exploration of autoimmune indications. The company's lead product, Orca-T, is a donor-derived cell therapy composed of precisely defined ratios of regulatory T-cells, hematopoietic stem cells, and conventional T-cells, manufactured through a proprietary single-cell precision platform that selects cell populations at single-cell resolution. The therapy is designed to balance immune reconstitution — reducing graft-versus-host disease (GvHD) while preserving the graft-versus-leukemia effect — and Phase 3 Precision-T data demonstrated statistically and clinically meaningful superiority over standard-of-care allogeneic transplant (78% one-year chronic GvHD-free survival vs. 38%; 94% overall survival vs. 83%; 3.4% non-relapse mortality vs. 13.2%).

Orca-T is currently under FDA Priority Review with a Biologics License Application (BLA) accepted in October 2025 and a PDUFA target action date of July 6, 2026. Manufacturing is centralized at a 100,000+ square-foot GMP facility in Sacramento, California, with a second East Coast GMP site in Princeton, New Jersey announced in June 2026, supported by a $100 million debt facility from Silicon Valley Bank. The platform has demonstrated a 100% on-time delivery rate within 70 hours across the Phase 3 program, an operational reliability benchmark that is material in the cell-therapy category.

The business model is currently pre-revenue and clinical-stage. Once approved, Orca Bio will generate revenue through one-time sales of allogeneic cell therapy products to hospital-based transplant centers, with cell therapies in this category historically priced in the high six figures per treatment. The company is actively building commercial infrastructure — appointing a Chief Commercial Officer (Mike Hirschmann, ex-Legend Biotech), a Chief Medical Officer, and a Chief Development Officer, and tripling the Sacramento workforce — and has retained BGR Government Affairs for policy and reimbursement advocacy ahead of launch. Cumulative equity raised exceeds $300 million, including a $192 million Series D in 2020 and a $250 million aggregate Series E/F round in late 2025/early 2026.

Short descriptiontext

Orca Bio is a late-stage clinical biotechnology company developing high-precision allogeneic T-cell immunotherapies for hematologic malignancies. Its lead product Orca-T, under FDA Priority Review with a July 2026 PDUFA date, uses single-cell precision to engineer defined cell compositions that reduce graft-versus-host disease.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersMenlo Park, United States
HQ citystring
Menlo Park
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
allogeneic cell therapy, T-cell immunotherapy, cell therapy manufacturing, biologics pipeline development, precision cell therapy
Industry3 codes
PRIMARYHLAAABAB
Cell Therapy Developers (Allogeneic/Off-the-shelf)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAC
CAR-T & TCR-T Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAIAAAC
Oncology & Hematology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Cell Therapy / Biologics
Social media profiles3 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Cell Therapy Product Sales
TypeOne Time License
Description

Once approved, Orca Bio will generate revenue through sale of its allogeneic T-cell immunotherapy products (Orca-T, Orca-Q) to transplant centers and hospitals treating patients with hematologic malignancies. The company is building commercial infrastructure including manufacturing capacity, distribution, and sales organization to support product commercialization.

businesswire.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1Orca-T
Description

Lead investigational allogeneic T-cell immunotherapy for treatment of hematologic malignancies including AML, ALL, and MDS.

orcabio.com
+2 more records
Core offering1 text field

Orca Bio develops high-precision allogeneic T-cell immunotherapies for the treatment of hematologic malignancies (AML, ALL, MDS, MPAL) and autoimmune diseases. Its products are manufactured using a proprietary single-cell precision platform that creates defined compositions of regulatory T-cells, hematopoietic stem cells, and conventional T-cells. The lead candidate Orca-T is under FDA Priority Review with a PDUFA date of July 6, 2026.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Survival free from moderate-to-severe chronic GvHD at one year: 78% with Orca-T vs 38% with conventional transplant (HR 0.26, p<0.00001)
+4 more records
Product overview1 text field

Orca Bio is a late-stage biotechnology company developing a portfolio of high-precision allogeneic T-cell immunotherapies for the treatment of blood cancers and autoimmune diseases. The company's product portfolio consists of three main investigational therapies: Orca-T (lead product candidate for AML, ALL, MDS, MPAL with FDA BLA under Priority Review), Orca-Q (second-generation therapy designed for broader donor compatibility including haploidentical donors), and OrCAR-T (combination of Orca-T with allogeneic CAR-T cells). All products are manufactured using the company's proprietary single-cell precision platform that enables precise compositions of regulatory T-cells, hematopoietic stem cells, and conventional T-cells to achieve balanced immune reconstitution while minimizing graft-versus-host disease.

Product and service3 records
1Orca-T
CategoryAllogeneic T-cell immunotherapy
Description

Orca-T is Orca Bio's lead investigational allogeneic T-cell immunotherapy for the treatment of hematologic malignancies including acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), myelodysplastic syndrome (MDS), and mixed-phenotype acute leukemia (MPAL). It is a precisely defined composition of regulatory T-cells, hematopoietic stem cells, and conventional T-cells derived from matched donor blood, designed to reduce graft-versus-host disease while preserving graft-versus-leukemia effect.

2Orca-Q
CategoryAllogeneic T-cell immunotherapy
Description

Orca-Q is Orca Bio's second-generation investigational allogeneic T-cell immunotherapy being evaluated in multiple hematologic malignancies, including in patients with haploidentical and mismatched donors. It is a proprietary composition of stem cells combined with specific T-cell subsets derived from healthy donors, designed for broader donor compatibility than Orca-T.

3OrCAR-T (Orca-T/CAR-T Combination)
Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierMinorTypeOthers
Description

Orca Bio registered as a new client with BGR Government Affairs in June 2026, engaging a three-person lobbying team (Remy Brim, John Stone, Brent Del Monte) for federal lobbying activity focused on medical research and clinical laboratory sectors.

Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Develops engineered T-cell therapies (SPEAR T-cells) for hematologic and solid tumors. Comparable as a late-stage cell therapy company targeting blood cancers.

TypeDirect peer
Description

Clinical-stage developer of allogeneic CAR-T cell therapies for hematologic malignancies. Closest direct peer to Orca Bio as another allogeneic cell therapy company targeting blood cancers.

TypeDirect peer
Description

Develops allogeneic T-cell and CAR-T immunotherapies for hematologic malignancies and solid tumors. Comparable as a fellow allogeneic T-cell therapy platform addressing transplant and oncology indications.

TypeDirect peer
Description

iPSC-derived NK and T-cell therapy developer for cancer and autoimmune disease. Comparable as an off-the-shelf cell therapy company targeting hematologic malignancies with an iPSC-based platform.

TypeDirect peer
Description

Developer of allogeneic CAR-T cell therapies using ARCUS gene editing for hematologic malignancies. Comparable as a fellow allogeneic cell therapy company in hematology.

TypeDirect peer
Description

Clinical-stage gene-edited allogeneic CAR-T developer (TALEN-based). Comparable as an allogeneic T-cell therapy company with a focus on hematologic malignancies.

TypeEmerging player
Description

Developer of allogeneic CAR-T cell therapies using CRISPR gene editing for hematologic malignancies. Comparable as an emerging allogeneic cell therapy peer.

TypeEmerging player
Description

Commercial-stage gene-editing company with Casgevy (exagamglogene autotemcel) approved for sickle cell disease and beta-thalassemia. Comparable in adjacent gene-edited cell therapy category with overlapping platform technologies.

TypeDirect peer
Description

Commercial-stage developer of Carvykti, an autologous BCMA CAR-T for multiple myeloma. Comparable as a CAR-T competitor in hematologic malignancies and source of Orca Bio's former CCO.

TypeBroad incumbent
Description

Owns Yescarta and Tecartus, leading autologous CD19 CAR-T franchises in lymphoma and ALL. Broad incumbent competing head-to-head with Orca-T in overlapping hematologic malignancy indications.

Market position
Strengths1 record

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors12 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Orca Bio

Cell Therapy / Biologicsorcabio.com

Orca Bio is a late-stage clinical biotechnology company developing high-precision allogeneic T-cell immunotherapies for hematologic malignancies. Its lead product Orca-T, under FDA Priority Review with a July 2026 PDUFA date, uses single-cell precision to engineer defined cell compositions that reduce graft-versus-host disease.

What Orca Bio does

Orca Bio is a late-stage clinical biotechnology company developing high-precision allogeneic T-cell immunotherapies for the treatment of hematologic malignancies, including acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), myelodysplastic syndromes (MDS), and mixed-phenotype acute leukemia (MPAL), with ongoing exploration of autoimmune indications. The company's lead product, Orca-T, is a donor-derived cell therapy composed of precisely defined ratios of regulatory T-cells, hematopoietic stem cells, and conventional T-cells, manufactured through a proprietary single-cell precision platform that selects cell populations at single-cell resolution. The therapy is designed to balance immune reconstitution — reducing graft-versus-host disease (GvHD) while preserving the graft-versus-leukemia effect — and Phase 3 Precision-T data demonstrated statistically and clinically meaningful superiority over standard-of-care allogeneic transplant (78% one-year chronic GvHD-free survival vs. 38%; 94% overall survival vs. 83%; 3.4% non-relapse mortality vs. 13.2%).

Orca-T is currently under FDA Priority Review with a Biologics License Application (BLA) accepted in October 2025 and a PDUFA target action date of July 6, 2026. Manufacturing is centralized at a 100,000+ square-foot GMP facility in Sacramento, California, with a second East Coast GMP site in Princeton, New Jersey announced in June 2026, supported by a $100 million debt facility from Silicon Valley Bank. The platform has demonstrated a 100% on-time delivery rate within 70 hours across the Phase 3 program, an operational reliability benchmark that is material in the cell-therapy category.

The business model is currently pre-revenue and clinical-stage. Once approved, Orca Bio will generate revenue through one-time sales of allogeneic cell therapy products to hospital-based transplant centers, with cell therapies in this category historically priced in the high six figures per treatment. The company is actively building commercial infrastructure — appointing a Chief Commercial Officer (Mike Hirschmann, ex-Legend Biotech), a Chief Medical Officer, and a Chief Development Officer, and tripling the Sacramento workforce — and has retained BGR Government Affairs for policy and reimbursement advocacy ahead of launch. Cumulative equity raised exceeds $300 million, including a $192 million Series D in 2020 and a $250 million aggregate Series E/F round in late 2025/early 2026.

Orca Bio firmographics

Firmographics
Name
Orca Bio
Legal name
Orca Biosystems Inc.
Website
https://orcabio.com
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
251–500 employees
Short description
Orca Bio is a late-stage clinical biotechnology company developing high-precision allogeneic T-cell immunotherapies for hematologic malignancies. Its lead product Orca-T, under FDA Priority Review with a July 2026 PDUFA date, uses single-cell precision to engineer defined cell compositions that reduce graft-versus-host disease.
Ownership category
akta.pro rank

Orca Bio industry classification

Industry
Product category
Cell Therapy / Biologics
NAICS
Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAABAB
Cell Therapy Developers (Allogeneic/Off-the-shelf)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAC
CAR-T & TCR-T Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAIAAAC
Oncology & Hematology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Allogeneic cell therapy
  • T-cell immunotherapy
  • Cell therapy manufacturing
  • Biologics pipeline development
  • Precision cell therapy

Where Orca Bio is headquartered

Location

Headquarters

HQ city
Menlo Park
HQ country
United States
HQ region
North America

Offices3 records

Markets served

Orca Bio business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales, Supply Chain

Revenue model

  1. Cell Therapy Product Sales: Once approved, Orca Bio will generate revenue through sale of its allogeneic T-cell immunotherapy products (Orca-T, Orca-Q) to transplant centers and hospitals treating patients with hematologic malignancies. The company is building commercial infrastructure including manufacturing capacity, distribution, and sales organization to support product commercialization.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Orca Bio product offering

Product offering

Core offering

Orca Bio develops high-precision allogeneic T-cell immunotherapies for the treatment of hematologic malignancies (AML, ALL, MDS, MPAL) and autoimmune diseases. Its products are manufactured using a proprietary single-cell precision platform that creates defined compositions of regulatory T-cells, hematopoietic stem cells, and conventional T-cells. The lead candidate Orca-T is under FDA Priority Review with a PDUFA date of July 6, 2026.

Product overview

Orca Bio is a late-stage biotechnology company developing a portfolio of high-precision allogeneic T-cell immunotherapies for the treatment of blood cancers and autoimmune diseases. The company's product portfolio consists of three main investigational therapies: Orca-T (lead product candidate for AML, ALL, MDS, MPAL with FDA BLA under Priority Review), Orca-Q (second-generation therapy designed for broader donor compatibility including haploidentical donors), and OrCAR-T (combination of Orca-T with allogeneic CAR-T cells). All products are manufactured using the company's proprietary single-cell precision platform that enables precise compositions of regulatory T-cells, hematopoietic stem cells, and conventional T-cells to achieve balanced immune reconstitution while minimizing graft-versus-host disease.

Differentiator

Problem solved

Functional benefit

Brands

  • Orca-T: Lead investigational allogeneic T-cell immunotherapy for treatment of hematologic malignancies including AML, ALL, and MDS.
  • Orca-Q
  • OrCAR-T (Orca-T/CAR-T Combination)

Products and services

  • Orca-T Orca-T is Orca Bio's lead investigational allogeneic T-cell immunotherapy for the treatment of hematologic malignancies including acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), myelodysplastic syndrome (MDS), and mixed-phenotype acute leukemia (MPAL). It is a precisely defined composition of regulatory T-cells, hematopoietic stem cells, and conventional T-cells derived from matched donor blood, designed to reduce graft-versus-host disease while preserving graft-versus-leukemia effect.
  • Orca-Q Orca-Q is Orca Bio's second-generation investigational allogeneic T-cell immunotherapy being evaluated in multiple hematologic malignancies, including in patients with haploidentical and mismatched donors. It is a proprietary composition of stem cells combined with specific T-cell subsets derived from healthy donors, designed for broader donor compatibility than Orca-T.
  • OrCAR-T (Orca-T/CAR-T Combination)

Quantifiable outcome

  • Survival free from moderate-to-severe chronic GvHD at one year: 78% with Orca-T vs 38% with conventional transplant (HR 0.26, p<0.00001)
  • +4 more outcomes

Companies that use Orca Bio

Customer profile

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Orca Bio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Orca Bio partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • BGR Government AffairsminorOthersOrca Bio registered as a new client with BGR Government Affairs in June 2026, engaging a three-person lobbying team (Remy Brim, John Stone, Brent Del Monte) for federal lobbying activity focused on medical research and clinical laboratory sectors.

Scale indicators5 records

Recent moves9 records

Expansion highlights7 records

Orca Bio competitors and assessment

Company assessment

Direct peers

  • Adaptimmune Therapeutics: Develops engineered T-cell therapies (SPEAR T-cells) for hematologic and solid tumors. Comparable as a late-stage cell therapy company targeting blood cancers.
  • Allogene Therapeutics: Clinical-stage developer of allogeneic CAR-T cell therapies for hematologic malignancies. Closest direct peer to Orca Bio as another allogeneic cell therapy company targeting blood cancers.
  • Atara Biotherapeutics: Develops allogeneic T-cell and CAR-T immunotherapies for hematologic malignancies and solid tumors. Comparable as a fellow allogeneic T-cell therapy platform addressing transplant and oncology indications.
  • Fate Therapeutics: iPSC-derived NK and T-cell therapy developer for cancer and autoimmune disease. Comparable as an off-the-shelf cell therapy company targeting hematologic malignancies with an iPSC-based platform.
  • Precision BioSciences: Developer of allogeneic CAR-T cell therapies using ARCUS gene editing for hematologic malignancies. Comparable as a fellow allogeneic cell therapy company in hematology.
  • Cellectis: Clinical-stage gene-edited allogeneic CAR-T developer (TALEN-based). Comparable as an allogeneic T-cell therapy company with a focus on hematologic malignancies.
  • Legend Biotech: Commercial-stage developer of Carvykti, an autologous BCMA CAR-T for multiple myeloma. Comparable as a CAR-T competitor in hematologic malignancies and source of Orca Bio's former CCO.

Emerging players

  • Caribou Biosciences: Developer of allogeneic CAR-T cell therapies using CRISPR gene editing for hematologic malignancies. Comparable as an emerging allogeneic cell therapy peer.
  • CRISPR Therapeutics: Commercial-stage gene-editing company with Casgevy (exagamglogene autotemcel) approved for sickle cell disease and beta-thalassemia. Comparable in adjacent gene-edited cell therapy category with overlapping platform technologies.

Broad incumbents

  • Gilead (Kite Pharma): Owns Yescarta and Tecartus, leading autologous CD19 CAR-T franchises in lymphoma and ALL. Broad incumbent competing head-to-head with Orca-T in overlapping hematologic malignancy indications.

Market position

Strengths1 record

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Orca Bio social profiles

Digital presence

Orca Bio compliance and trust

Trust signal

Compliance4 records

Orca Bio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Orca Bio leadership team

Management profile

Number of profiles

Profiles10 records

Orca Bio funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors12 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Orca Bio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Orca Bio

What does Orca Bio do?

Orca Bio develops high-precision allogeneic T-cell immunotherapies for the treatment of hematologic malignancies (AML, ALL, MDS, MPAL) and autoimmune diseases. Its products are manufactured using a proprietary single-cell precision platform that creates defined compositions of regulatory T-cells, hematopoietic stem cells, and conventional T-cells. The lead candidate Orca-T is under FDA Priority Review with a PDUFA date of July 6, 2026.

Is Orca Bio a public or private company?

Orca Bio is a private company. It is classified as venture growth investor backed and is currently operating.

When was Orca Bio founded?

Orca Bio was founded in 2016. It employs 251 to 500 people.

Where is Orca Bio based?

Orca Bio is headquartered in Menlo Park, United States, in the North America region.

How does Orca Bio make money?

One revenue line is on record: cell Therapy Product Sales.

Who are Orca Bio's main competitors?

Direct peers on record are Adaptimmune Therapeutics, Allogene Therapeutics, Atara Biotherapeutics, Fate Therapeutics, Precision BioSciences, Cellectis and Legend Biotech. Emerging players are Caribou Biosciences and CRISPR Therapeutics. Gilead (Kite Pharma) is listed as a broad incumbent.

Does Orca Bio have an API?

No public API is recorded for Orca Bio.

What industry is Orca Bio in?

Orca Bio's product category is Cell Therapy / Biologics. Its primary akta.pro industry code is HLAAABAB, Cell Therapy Developers (Allogeneic/Off-the-shelf), with a secondary code of HLAAABAC, CAR-T & TCR-T Therapies. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireMade Scientific Announces Long-Term Commercial Manufacturing Partnership with Orca Bio for TREGZI™Made Scientific and Orca Bio announced a long-term commercial manufacturing partnership for TREGZI, with Made Scientific providing East Coast capacity in Princeton, New Jersey. The Princeton site complements Orca Bio's Sacramento facility, enabling a bicoastal network and European donor sourcing. Made Scientific plans to expand its Princeton campus by 45,000 sq. ft. to support growth.Business & FinancialMyelodysplastic Syndrome Market Projected To Achieve Substantial Growth By 2036, Led By Key Companies And Strategic Developments Geron, Servier, Abbvie, Orcabio, Rigel Pharma, Fibrogen, AbbvieThe myelodysplastic syndrome market was valued at approximately $4.3 billion in 2025 across the US, EU4, UK, and Japan. Bristol Myers Squibb initiated a clinical trial for luspatercept, while other companies advanced or discontinued therapies like LYT-200 and SL-172154. The market is projected to grow substantially by 2036.Business Wire BlogOrca Bio to Present New Data on TREGZI® and the Company’s Clinical Pipeline at the 68th Annual American Society of Hematology Annual MeetingOrca Bio will present new clinical data at the ASH Annual Meeting, including two-year follow-up from the Phase 3 Precision-T trial of TREGZI. The company also plans to share preliminary outcomes of Orca-Q and Orca-T in various transplant settings.FinancialContent Business PageOrca Bio to Present New Data on TREGZI® and the Company’s Clinical Pipeline at the 68th Annual American Society of Hematology Annual MeetingOrca Bio will present four poster sessions at the ASH Annual Meeting, including two-year follow-up from the Phase 3 Precision-T trial of TREGZI. The data show durable survival outcomes versus conventional allogeneic transplant, plus preliminary results on Orca-Q and Orca-T in various conditioning regimens.BioSpaceOrca Bio Announces the Publication of TREGZI™ Long-Term Overall Survival Data in Transplantation and Cellular TherapyOrca Bio published three-year overall survival data from a retrospective analysis comparing TREGZI to post-transplant cyclophosphamide (PTCy) in hematologic malignancies. TREGZI showed higher survival (HR=0.41, p=0.003), with 83% three-year OS versus 66% for PTCy. The findings reinforce the potential of high-precision graft engineering to improve long-term outcomes.BioSpaceOrca Bio to Present Clinical Data on TREGZI™ and Its Clinical Pipeline at the 14th Annual Meeting of the Society of Hematologic OncologyOrca Bio announced three clinical data presentations at the 14th Annual Meeting of the Society of Hematologic Oncology in Houston, including TREGZI infection data from the Precision-T Phase 3 trial and Orca-Q preliminary safety in haploidentical donors. The company also presented the SERENE-T trial design for older patients with hematologic malignancies.Business Wire BlogOrca Bio to Present Clinical Data on TREGZI™ and Its Clinical Pipeline at the 14th Annual Meeting of the Society of Hematologic OncologyOrca Bio announced three clinical data presentations at the 14th Annual Meeting of the Society of Hematologic Oncology in Houston, September 9-12. The presentations cover TREGZI infection events from the Precision-T Phase 3 trial, Orca-Q preliminary safety in haploidentical donors, and the Serene-T trial design. Copies will be available on the company's website.Targeted OncologyFDA Extends Review Timeline of Orca-T for MDS, LeukemiaThe FDA extended the review deadline for Orca-T, an allogeneic T-cell immunotherapy for MDS and acute leukemias, to July 6, 2026. The extension followed a Major Amendment submission without new clinical data requests. Orca Bio expects a potential mid-2026 launch pending approval.Cancer NetworkFDA Extends Review Period for Orca-T in Hematologic MalignanciesThe FDA extended the review period for Orca-T's biologics license application to July 6, 2026, after Orca Bio submitted a major amendment. No additional clinical findings were requested, and the updated data should not affect the benefit-risk profile. The company remains focused on preparing for potential approval and commercial launch.pharmaphorumFDA clears Orca's cell therapy Tregzi for GvHDThe FDA approved Orca Bio's Tregzi, a cell therapy to prevent graft-versus-host disease in bone marrow transplant patients. In a trial of 187 patients, chronic GVHD occurred in 13% with Tregzi versus 44% in the control group, and chronic GVHD-free survival was 78% versus 38%. The therapy is priced at $428,000 wholesale acquisition cost.